149 related articles for article (PubMed ID: 32816219)
21. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
Bonny A; Talle MA; Ngantcha M; Tayebjee MH
Travel Med Infect Dis; 2020; 37():101861. PubMed ID: 32889105
[No Abstract] [Full Text] [Related]
22. Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19.
Rosenberg ES; Holtgrave DR; Udo T
Int J Infect Dis; 2020 Oct; 99():38-39. PubMed ID: 32738483
[No Abstract] [Full Text] [Related]
23. Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
d'Arminio Monforte A; Tavelli A; Bai F; Marchetti G; Cozzi-Lepri A
Int J Infect Dis; 2020 Oct; 99():75-76. PubMed ID: 32738491
[No Abstract] [Full Text] [Related]
24. Hydroxychloroquine in COVID-19: Taking care of statistics to take care of patients.
Brito-Azevedo A
Int J Infect Dis; 2020 Oct; 99():324. PubMed ID: 32768698
[No Abstract] [Full Text] [Related]
25. Risch Responds to "How to Consider Low Reported Death Rates in COVID-19".
Risch HA
Am J Epidemiol; 2020 Nov; 189(11):1230-1231. PubMed ID: 32685962
[No Abstract] [Full Text] [Related]
26. Deploying Randomized Controlled Trials during the COVID-19 Pandemic: Reason and Bayesian Designs.
Zampieri FG
Ann Am Thorac Soc; 2020 Aug; 17(8):937-938. PubMed ID: 32735169
[No Abstract] [Full Text] [Related]
27. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
Decloedt EH; Reuter H; Allwood B; Parker A; Koegelenberg CFN; Blockman M; Taljaard J
S Afr Med J; 2020 Apr; 110(5):12903. PubMed ID: 32657706
[No Abstract] [Full Text] [Related]
28. Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Miller MC; Abraham GM; Obley AJ; Forciea MA; Jokela JA; Humphrey LL;
Ann Intern Med; 2020 Jul; 173(2):W48-W51. PubMed ID: 32551892
[No Abstract] [Full Text] [Related]
29. Practical implementation of COVID-19 patient flags into an antimicrobial stewardship program's prospective review.
Stevens RW; Estes L; Rivera C
Infect Control Hosp Epidemiol; 2020 Sep; 41(9):1108-1110. PubMed ID: 32290883
[No Abstract] [Full Text] [Related]
30. Audio Interview: Studying Potential Covid-19 Therapies.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(19):e72. PubMed ID: 32379957
[No Abstract] [Full Text] [Related]
31. The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials.
Malviya A
Int J Infect Dis; 2020 Oct; 99():310-311. PubMed ID: 32738490
[No Abstract] [Full Text] [Related]
32. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA).
Dar SA; Wahid M; Haque S; Almalki SS; Akhter N
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):7923-7924. PubMed ID: 32767316
[No Abstract] [Full Text] [Related]
33. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
[No Abstract] [Full Text] [Related]
34. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
Bessière F; Roccia H; Delinière A; Charrière R; Chevalier P; Argaud L; Cour M
JAMA Cardiol; 2020 Sep; 5(9):1067-1069. PubMed ID: 32936266
[TBL] [Abstract][Full Text] [Related]
35. RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS".
Peiffer-Smadja N; Costagliola D
Am J Epidemiol; 2020 Nov; 189(11):1443-1444. PubMed ID: 32685975
[No Abstract] [Full Text] [Related]
36. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial.
Hinks TSC; Barber VS; Black J; Dutton SJ; Jabeen M; Melhorn J; Rahman NM; Richards D; Lasserson D; Pavord ID; Bafadhel M
Trials; 2020 Aug; 21(1):718. PubMed ID: 32807209
[TBL] [Abstract][Full Text] [Related]
37. Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic.
Capucci A; Santarelli A; Bartolomei M; Paolizzi C; Biagetti C; Dappozzo A; Piovaccari G
J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):922-923. PubMed ID: 32740441
[No Abstract] [Full Text] [Related]
38. Auditory Cinchonism in COVID Era.
Saniasiaya J; Kulasegarah J
Ear Nose Throat J; 2020 Nov; 99(9):597-598. PubMed ID: 32744901
[No Abstract] [Full Text] [Related]
39. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
Roden DM; Harrington RA; Poppas A; Russo AM
Circulation; 2020 Jun; 141(24):e906-e907. PubMed ID: 32267732
[No Abstract] [Full Text] [Related]
40. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.
Aggarwal G; Henry BM; Aggarwal S; Bangalore S
Am J Cardiol; 2020 Aug; 128():147-150. PubMed ID: 32425199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
